Cardiomyopathy Trial, Recruiting NCT06040242 Sponsor: Swiss Federal Institute of Technology Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06040242
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been formally diagnosed with a heart condition called ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy) based on specific medical guidelines from 2010
  • You carry a known or likely harmful change (variant) in one of three specific heart-related genes (PKP-2, DSG-2, or DSP), OR you had genetic testing done but no such variant was found
  • (For a comparison group only) You have been diagnosed with heart disease caused by blocked arteries, and your heart pumping strength is above 35%
  • Your heart doctor agrees that taking part in this study would not involve more physical activity than is safe for you personally
  • You have not fainted during exercise in the 6 months before joining the study
  • You have not had a cardiac arrest (heart suddenly stopping) in the 6 months before joining the study
  • If you have previously had a cardiac arrest or fainted due to a heart rhythm problem, you must have an implanted heart device (ICD) fitted and be taking heart-related medications (beta-blockers or antiarrhythmic drugs)
  • You are older than 14 years of age
  • Your body weight falls within a moderate range (BMI between 18.5 and 39.9) (confirm with trial site)
  • You are willing to follow specific rules before testing, such as avoiding intense exercise for 48 hours beforehand, getting enough sleep, and avoiding caffeine and alcohol on test days
  • You agree to continue taking all your regular medications as prescribed
  • You have signed a form confirming you understand and agree to take part

Who may not be able to join:

  • You have never had genetic testing to check for ARVC-related gene variants
  • Your heart's pumping ability is severely reduced (left ventricular ejection fraction below 35%)
  • You are pregnant, breastfeeding, or planning to become pregnant during the study (applies to women)
  • You are known or suspected to misuse drugs or alcohol, or are unlikely to follow the study rules
  • You are unable to follow the study procedures — for example, due to language barriers, psychological conditions, or dementia
  • You have already taken part in this study before

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christina M Spengler, PhD, MD, ETH Zurich, Exercise Physiology Lab, Institute of Human Movement Sciences and Sport

Phone: +41446330472

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Swiss Federal Institute of Technology
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

count of premature ventricular beats during and after the activities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov